98. Pagano C, y cols. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calciumdependent mechanisms. Journal of Clinical Endocrinology and Metabolism 2007. 92 4810–4819.
99. Bensaid M, y cols. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63: 904-914.
100. Matias I, y cols. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. Journal of Clinical Endocrinology and Metabolism 2006. 91 3171–3180.
101. Matias I, Cristino L, Di Marzo V. Endocannabinoids: some like it fat (and sweet too). J Neuroendocrinol. 2008; 20 Suppl 1:100-9.
102. Kola B, y cols. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. Journal of Biological Chemistry 2005. 280 25196–25201.
103. Pagano C, Rossato M, Vettor R. Endocannabinoids, adipose tissue and lipid metabolism. J Neuroendocrinol. 2008. 20 Suppl 1:124-9.
104. Jbilo O, y cols. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB Journal 2005 19 1567–1569.
105. Jesudason D & Wittert G. Endocannabinoid system in food intake and metabolic regulation. Current Opinion in Lipidology 2008. 19 344–348.
106. Gary-Bobo M, y cols. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 2007. 46 122–129.
107. Zbucki RL, Sawicki B, et al. Cannabinoids enhance gastric X/A-like cells activity. Folia Histochem Cytobiol. 2008; 46(2):219-24.
108. R. Nogueiras, y cols. The Endocannabinoid System and the Control of Glucose Homeostasis. J Neuroendocrinol. 2008. 20 Suppl 1:147-151.
109. Nakata M, Yada T. Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet beta-cells via CB1 receptors. Regul Pept (2008) 145:49–53.
110. Joyal SV. A perspective on the current strategies for the treatment of obesity. Curr Drug Targets CNS Neurol Disord. 2004; 3:341-56.
111. Gutt S. Tratamiento farmacológico de la obesidad. Abordaje farmacológico. Rev. Hosp. Ital. B Aires. 2009; Vol. 29. Nº 1. 10-16.
112. Makriyannis A, Mechoulam R, Piomelli D. Therapeutic opportunities through modulation of the endocannabinoid system. Neuropharmacology (2005) 48 1068-1071.
113. Rinaldi-Carmona M, y cols. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letters 1994. 350 240–244.
114. Van Gaal LF, y cols. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005. 365 1389–1397.
115. Pi-Sunyer FX, y cols. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. Journal of the American Medical Association 2006. 295 761–775.
116. Despres JP, Golay A & Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New England Journal of Medicine 2005. 353 2121–2134.
117. Scheen AJ, y cols. Efficacy and tolerability of rimonabant in overweight or obese
patients with type 2 diabetes: a randomised controlled study. Lancet 2006. 368 1660–1672.
118. Scheen AJ. Effects of rimonabant in patients with type 2 diabetes mellitus. Results of the RIO DIABETES trial. Paper presented at American Diabetes Association, San Diego, CA, 2005.
119. Nissen SE, y cols. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. Journal of the American Medical Association 2008. 299 1547–1560.
120. Butler H & Korbonits M. Cannabinoids for clinicians: the rise and fall of the cannabinoid Antagonists. European Journal of Endocrinology (2009) 161 655–662.
121. Ohlsen R, Pilowsky L. The place of partial agonism in psychiatry: recent developments. J Psychopharmacol 2005; 19 (4): 408-13.
122. Fisas A, y cols. Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats. British Journal of Pharmacology 2006. 148 973–983.